Talia Puzantian, PharmD, BCPP

Medication Fact Book For Psychiatric Practice, Fourth Edition (2018)

PDF Access and CME Post-Test

February 28, 2018

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have disclosed that they has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Downloading your PDF and eBook copies and complete the CME Post-Test for The Medication Fact Book for Psychiatric Practice, Fourth Edition (2018).

Treating Opioid Use Disorder—A Fact Book (2024)

PDF/eBook and CME Access

February 28, 2017

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD, have no financial or other interests in any commercial companies pertaining to this educational activity.

This page has links and instructions for downloading your PDF and eBook copies of Treating Opioid Use Disorder—A Fact Book (2024). All versions of this product include access to the 8 CME Post-Test.

Treating Opioid Use Disorder—A Fact Book (2024)

Print Copy With PDF/eBook and CME Access

February 28, 2017

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD, have no financial or other interests in any commercial companies pertaining to this educational activity.

This page has links and instructions for downloading your PDF and eBook copies of Treating Opioid Use Disorder—A Fact Book (2024). All versions of this product include access to the 8 CME Post-Test.

Treating Alcohol Use Disorder—A Fact Book (2023)

PDF/eBook and CME Access

February 28, 2017

Daniel Carlat, MD, Michael Weaver, MD, and Talia Puzantian, PharmD, BCPP

Daniel Carlat, MD, Michael Weaver, MD, and Talia Puzantian, PharmD, BCPP, have no financial or other interests in any commercial companies pertaining to this educational activity.

This page has links and instructions for downloading your PDF and eBook copies of Treating Alcohol Use Disorder—A Fact Book (2023). All versions of this product include access to the 6 CME Post-Test.

Treating Alcohol Use Disorder—A Fact Book (2023)

Print Copy with PDF/eBook and CME Access

February 28, 2017

Daniel Carlat, MD, Michael Weaver, MD, and Talia Puzantian, PharmD, BCPP

Daniel Carlat, MD, Michael Weaver, MD, and Talia Puzantian, PharmD, BCPP, have no financial or other interests in any commercial companies pertaining to this educational activity.

This page has links and instructions for downloading your PDF and eBook copies of Treating Alcohol Use Disorder—A Fact Book (2023). All versions of this product include access to the 6 CME Post-Test.

Identifying and Deterring Drug Abuse and Diversion via PDMPs

November 1, 2016

Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP Deputy Editor, The Carlat Psychiatry Report Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How do PDMPs work? To search for a patient in a PDMP, all you need to do is enter the person’s name and birthdate and click the search button. The PDMP will generate a patient activity report that will tell you what controlled substances the patient has picked up and where. The report gives you lots of detail, including the address of the patient; the drug names, doses, quantities, and refill information on any controlled substances that have been dispensed; and the applicable prescriber names, DEA numbers, pharmacy names, dispensing dates, and prescription numbers.

What’s New with the FDA Labeling for Pregnancy and Lactation?

July 1, 2016

Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP Deputy Editor, The Carlat Psychiatry Report Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We’ve been hearing for some time now about the FDA’s plans to revise the long-standing categories A, B, C, D, and X designations for risk of using medications in pregnancy. The new rule (referred to as PLLR for Pregnancy and Lactation Labeling Rule) was proposed in 2008, finalized in 2014, and implementation began during the summer of 2015.

Four Newer Antidepressants: Should You Use Them?

April 1, 2016

Steve Balt, MD and Talia Puzantian, PharmD, BCPP

Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb. Talia Puzantian, PharmD, BCPP Clinical psychopharmacology consultant in private practice, Los Angeles, CA. Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Since 2011, 3 new antidepressants have been approved by the FDA, and another (ketamine) has been generating buzz as a potential off-label medication for depression. In this article, we’ll take a step back and review the data on vilazodone (Viibryd), levomilnacipran (Fetzima), vortioxetine (Brintellix), and ketamine.

The Medication Fact Book for Psychiatric Practice, Third Edition (2016)

PDF Access and CME Post-Test

February 29, 2016

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

PDF and E-Book Access to The Medication Fact Book for Psychiatric Practice, Third Edition (2016) and the 8 CME post-test

Intranasal Naloxone Product Approved by FDA

January 1, 2016

Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP

Clinical psychopharmacology consultant, www.taliapuzantian.com

Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

The opioid antagonist, naloxone, was first approved for opioid overdose treatment in 1971 and is available as an inexpensive injectable generic. In recent years, emergency responders have been using more easily administered intranasal version of naloxone.